|
|
|
| Effect ticagrelor and clopidogrel on platelet function and platelet inhibition in patients with ACS after PCI |
| ZHENG Yan-e, LUO Hui, YANG Hang, et al |
| Department of Emergency Internal Medicine, Longgang Central Hospital of Shenzhen City, 518116, China |
|
|
|
|
Abstract 【Objective】To investigate and compare the effect of ticagrelor and clopidogrel on platelet function and platelet inhibition in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). 【Methods】A total of 106 cases of ACS patients undergoing elective PCI in the hospital were divided into the ticagrelor group and the clopidogrel group by random number table method, 53 cases in each group. The maximum platelet aggregation rate (MPAR) and plasma P2Y12 response uni (PRU) were compared. The resistance to antiplatelet drugs in 24 hours after PCI was determined with arachidonic acid (AA) and adenosine diphosphate (ADP) as activators. All patients were followed up for 1 year after operation, the incidence of clinical end point events was recorded, and adverse drug reactions were statistically analyzed. 【Results】 24 hours and 7 days after operation, MPAR and PRU were lower in ticagrelor group than clopidogrel group ( P < 0.05). ADP inhibition rate was higher in ticagrelor group than clopidogrel group, and the proportion of ADP inhibitor < 30% was significantly lower in ticagrelor group than clopidogrel group (3.77% vs 32.08%) ( P < 0.05). The incidence of clinical end point events in ticagrelor group in 1 year after operation was lower than that in clopidogrel group (11.32% vs 33.96%) (χ2=7.756, P < 0.05). The incidence of adverse drug reactions showed no significant difference between the two groups (16.98% vs 13.21%) (χ2=0.294, P > 0.05). 【Conclusion】Ticagrelor is superior to clopidogrel in inhibiting platelet aggregation after PCI in patients with ACS, and the incidence of tigrilol resistance is lower, which could reduce the incidence of clinical endpoint events and had high safety.
|
|
Received: 01 April 2017
|
|
|
|
|
|
[1] 谭艳武,罗伟陵,赵迪诚.老年不稳定型心绞痛患者P2Y12受体基因多态性对氯吡格雷抑制血小板聚集率的影响[J].湖南师范大学学报(医学版),2014,11(2):49-51.
[2] 邢志芳,程晓文,潘晓燕,等.CYP2C19基因多态性对PCI术后氯吡格雷反应性的影响[J].血栓与止血学,2015,21(5):266-269.
[3] James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial[J]. BMJ Br Med J, 2011, 342(7812):1403. [4] 程晓曙,杨人强.2011美国心脏病学基金会/美国心脏学会2007版《不稳定心绞痛/非ST段抬高心肌梗死患者管理指南》解读[J].江西医药, 2012,47(5):378-380.
[5] 赵菁,耿文静,翟博智等.血栓通注射液治疗急性脑梗死氯吡格雷抵抗的临床观察[J].中草药,2015,46(14):2122-2126
[6] 范吉利,尚文涛,周元松,等.盐酸替罗非班联合替格瑞洛在急性冠脉综合征合并糖尿病患者 PCI 围术期的安全性研究[J].医学临床研究,2016,33(6):1239-1240,1241.
[7] 楼善杰,黄诚意,朱劲草,等.替格瑞洛治疗急性冠状动脉综合征疗效观察[J].中华实用诊断与治疗杂志,2015,29(1):90-92.
[8] Kern MJ.Conversations in cardiology: using new media to transmit timely medical knowledge. How do you assess the left main stenosis with FFR and IVUS in a patient with multivessel CAD[J]? Catheter Cardiovasc Interv, 2012, 80(3):465.
[9] 高鹏,仲宁,畅君毅.替格瑞洛与氯吡格雷对急性冠脉综合征患者PCI术后血小板功能和炎症因子的影响[J].中国循证心血管医学杂志,2015,7(6):763-766. |
|
|
|
2018, Vol. 35 
